Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | TLR4 | O00206 | 4/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 6/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779128 | 1.00 | MAPT (0.47) | MAPTTLR4ABCB1GAATP53 | |
| SCHEMBL25412997 | 0.88 | MAPT (0.49) | MAPTGAANPSR1LMNANPC1 | |
| SCHEMBL29270703 | 0.88 | MAPT (0.49) | MAPTGAANPSR1LMNANPC1 | |
| SCHEMBL26349860 | 0.88 | MAPT (0.49) | MAPTGAANPSR1LMNANPC1 | |
| SCHEMBL502387 | 0.86 | ABCB1 (0.53) | MAPTABCB1GAATP53LMNA | |
| SCHEMBL14141132 | 0.86 | CYP1A2 (0.50) | MAPTABCB1GAATP53NPSR1 | |
| SCHEMBL10056749 | 0.86 | ABCB1 (0.53) | MAPTABCB1GAATP53LMNA | |
| SCHEMBL502388 | 0.86 | ABCB1 (0.53) | MAPTABCB1GAATP53LMNA | |
| SCHEMBL14275243 | 0.85 | TSHR (0.44) | MAPTABCB1GAANPSR1LMNA | |
| SCHEMBL23367256 | 0.85 | MAPT (0.44) | MAPTTLR4ABCB1GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309571-B2 | Heterobicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110190292-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-7943617-B2 | Especially p38 MAP kinase alpha and beta; 2,4-difluorophenyl(3-(2-(trifluoromethyl)phenyl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)methanone | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20080275052-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275052-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP2K2, MAP2K6, MAP2K1 | MAPT 2445/4885TLR4 4665/4885ABCB1 420/4885 |
| US-20110190292-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP2K2, MAP2K6, MAP2K1 | MAPT 2445/4885TLR4 4665/4885ABCB1 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.